

Special Issue

Epidemiological Approaches to Understanding the Role of Environmental and Sociodemographic Factors in Vaccine-Preventable Diseases

Message from the Guest Editors

The international and multidisciplinary efforts to develop vaccines and other public health strategies to address the Covid-19 pandemic demonstrated our capacity to respond to health issues with global impact but also highlighted the looming threat of emerging infectious diseases. These factors can also affect the effectiveness of vaccination programs and disease prevention strategies. This special issue aims to provide updated and high-quality evidence to support prevention strategies with an emphasis on vaccination to address the significant and increasing challenges posed by infections that include (but are not limited to): Influenza, Japanese encephalitis, Yellow fever, Pneumococcal and Meningococcal disease, Rotavirus, Tetanus (non-neonatal), Dengue, Ebola, Hepatitis (A/B), Mumps, Typhoid, Varicella, Rubella, Measles, Malaria, Leishmaniasis and Schistosomiasis, as well as emerging infections such as COVID-19 and Monkeypox.

Guest Editors

Prof. Dr. Wenbiao Hu

School of Public Health and Social Work, Queensland University of Technology, Brisbane, QLD 4000, Australia

Dr. Javier Cortes-Ramirez

School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia

Deadline for manuscript submissions

closed (31 May 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/142987

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).